Bruce Keyt Sells 10,000 Shares of IGM Biosciences, Inc. (NASDAQ:IGMS) Stock
Bruce Keyt Sells 10,000 Shares of IGM Biosciences, Inc. (NASDAQ:IGMS) Stock
IGM Biosciences, Inc. (NASDAQ:IGMS – Get Rating) insider Bruce Keyt sold 10,000 shares of IGM Biosciences stock in a transaction that occurred on Thursday, September 8th. The shares were sold at an average price of $19.78, for a total transaction of $197,800.00. Following the sale, the insider now owns 39,489 shares of the company's stock, valued at $781,092.42. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
IGM生物科学公司(纳斯达克代码:IGMS-GET Rating)内部人士Bruce KEYT在9月8日星期四的一笔交易中出售了10,000股IGM生物科学公司的股票。这些股票以19.78美元的平均价格出售,总成交金额为197,800.00美元。出售后,这位内部人士现在持有该公司39,489股股票,价值781,092.42美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可以在美国证券交易委员会网站上找到。
Bruce Keyt also recently made the following trade(s):
布鲁斯·凯伊特最近还进行了以下交易:
- On Tuesday, September 6th, Bruce Keyt sold 5,000 shares of IGM Biosciences stock. The shares were sold at an average price of $19.06, for a total transaction of $95,300.00.
- On Friday, August 19th, Bruce Keyt sold 8,700 shares of IGM Biosciences stock. The shares were sold at an average price of $22.82, for a total transaction of $198,534.00.
- On Monday, August 22nd, Bruce Keyt sold 6,300 shares of IGM Biosciences stock. The stock was sold at an average price of $20.71, for a total transaction of $130,473.00.
- 9月6日,星期二,Bruce KEYT出售了5,000股IGM Biosciences股票。这些股票以19.06美元的平均价格出售,总成交金额为95,300.00美元。
- 8月19日,星期五,Bruce KEYT出售了8,700股IGM Biosciences股票。这些股票以22.82美元的平均价格出售,总成交金额为198,534.00美元。
- 8月22日,星期一,Bruce KEYT出售了6,300股IGM Biosciences的股票。该股以20.71美元的平均价格出售,总成交金额为130,473.00美元。
IGM Biosciences Stock Performance
IGM Bioscions股票表现
IGMS stock opened at $21.25 on Friday. The stock has a market capitalization of $903.76 million, a P/E ratio of -3.74 and a beta of -0.32. IGM Biosciences, Inc. has a one year low of $12.67 and a one year high of $76.20. The company has a 50 day moving average price of $20.04 and a two-hundred day moving average price of $18.47.
IGMS股票上周五开盘报21.25美元。该股市值为9.0376亿美元,市盈率为-3.74,贝塔系数为-0.32。IGM Biosciences,Inc.的一年低点为12.67美元,一年高位为76.20美元。该公司的50日移动均线价格为20.04美元,200日移动均线价格为18.47美元。
Hedge Funds Weigh In On IGM Biosciences
对冲基金参与IGM生物科学
Hedge funds and other institutional investors have recently made changes to their positions in the business. Point72 Hong Kong Ltd acquired a new position in shares of IGM Biosciences during the 4th quarter valued at $34,000. Amalgamated Bank acquired a new position in IGM Biosciences in the 1st quarter worth $36,000. US Bancorp DE lifted its holdings in IGM Biosciences by 608.4% in the 1st quarter. US Bancorp DE now owns 2,437 shares of the company's stock worth $65,000 after buying an additional 2,093 shares in the last quarter. Captrust Financial Advisors acquired a new position in IGM Biosciences in the 2nd quarter worth $50,000. Finally, American International Group Inc. lifted its holdings in IGM Biosciences by 15.0% in the 2nd quarter. American International Group Inc. now owns 4,684 shares of the company's stock worth $84,000 after buying an additional 612 shares in the last quarter. Institutional investors and hedge funds own 41.20% of the company's stock.
对冲基金和其他机构投资者最近对他们在该业务中的头寸进行了调整。Point72 Hong Kong Ltd于第四季度收购了价值34,000美元的IGM Biosciences股票的新头寸。合并银行在第一季度收购了IGM Biosciences的一个新头寸,价值3.6万美元。美国Bancorp DE在第一季度增持了IGM Biosciences 608.4%的股份。US Bancorp DE现在拥有2437股该公司股票,价值6.5万美元,此前在上个季度又购买了2093股。CapTrust Financial Advisors在第二季度收购了IGM Biosciences的一个新头寸,价值5万美元。最后,美国国际集团(American International Group Inc.)在第二季度增持了IGM Biosciences 15.0%的股份。美国国际集团目前持有该公司4,684股股票,价值84,000美元,此前该公司在上个季度又购买了612股。机构投资者和对冲基金持有该公司41.20%的股票。
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
IGMS has been the subject of a number of recent research reports. Guggenheim dropped their price objective on shares of IGM Biosciences to $40.00 in a research note on Monday, August 15th. Bank of America initiated coverage on shares of IGM Biosciences in a research note on Monday, August 29th. They set a "buy" rating and a $34.00 price objective for the company. HC Wainwright dropped their price objective on shares of IGM Biosciences from $59.00 to $58.00 and set a "buy" rating for the company in a research note on Tuesday, May 17th. Truist Financial dropped their price objective on shares of IGM Biosciences from $74.00 to $37.00 and set a "buy" rating for the company in a research note on Tuesday, August 23rd. Finally, Robert W. Baird lowered their target price on shares of IGM Biosciences from $46.00 to $31.00 and set an "outperform" rating for the company in a research note on Wednesday, June 1st. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $53.00.
政府间海洋生态系统是最近一些研究报告的主题。古根海姆在8月15日星期一的一份研究报告中将IGM Biosciences的股票目标价下调至40.00美元。美国银行在8月29日星期一的一份研究报告中启动了对IGM Biosciences股票的报道。他们为该公司设定了“买入”评级和34.00美元的目标价。5月17日,周二,HC Wainwright在一份研究报告中将IGM Biosciences的股票目标价从59.00美元下调至58.00美元,并为该公司设定了“买入”评级。Truist Financial在8月23日(星期二)的一份研究报告中将IGM Biosciences的股票目标价从74.00美元下调至37.00美元,并为该公司设定了“买入”评级。最后,罗伯特·W·贝尔德在6月1日星期三的一份研究报告中将IGM Biosciences的股票目标价从46.00美元下调至31.00美元,并为该公司设定了“跑赢大盘”的评级。两名股票研究分析师对该股的评级为持有,七名分析师对该公司的评级为买入。根据MarketBeat的数据,该公司目前的共识评级为“适度买入”,共识目标价为53.00美元。
IGM Biosciences Company Profile
IGM生物科学公司简介
(Get Rating)
(获取评级)
IGM Biosciences, Inc, a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL).
IGM生物科学公司是一家生物技术公司,开发用于治疗癌症、传染病、自身免疫性疾病和炎症性疾病的免疫球蛋白M(IgM)抗体。该公司的主要候选产品是IGM-2323,这是一种双特异性IgM抗体,正处于第二阶段临床试验,用于治疗复发/难治性B细胞非霍奇金淋巴瘤(NHL)患者。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on IGM Biosciences (IGMS)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- 免费获取StockNews.com关于IGM生物科学的研究报告(IGMS)
- MarketBeat:回顾一周9/5-9/9
- 为网络安全股创纪录的季度做准备
- 汽车市场正在缓慢复苏,这些股票可能表现优异
- DocuSign是否即将发生重大逆转?
- 石油和天然气股票:投资可再生能源的安全途径
Receive News & Ratings for IGM Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IGM Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受IGM《生物科学日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对IGM Biosciences和相关公司的最新新闻和分析师评级的每日简明摘要。